

From: Paul Morris <[REDACTED]>

To: "jeffrey E." <jeevacation@gmail.com>

Subject: quick discussion about pharma financing opportunity? [C]

Date: Thu, 14 May 2015 16:07:08 +0000

Inline-Images: image006.png

Classification: **Confidential**

jeffrey, we are working on a live situation with a pharma company that is looking to finance the distribution and sales of a newly approved drug. DB is bidding on the debt financing and would need to syndicate out ~\$50mm to a third party. I expect the transaction to be structured as a royalty arrangement and imagine yields would be in the low double digits. I know you've done equity transactions in biotech area over the years but thought you may have someone interested in a discussion with our structured credit team to see if this would be a fit? Let's catch up soon.

Hope all is well,

Paul Morris
Managing Director
Deutsche Bank Private Bank

[REDACTED]
[REDACTED]

cid:image006.png

Securities offered through Deutsche Bank Securities Inc.

This communication may contain confidential and/or privileged information. If you are not the intended recipient (or have received this communication in error) please notify the sender immediately and destroy this communication. Any unauthorized copying, disclosure or distribution of the material in this communication is strictly forbidden.

Deutsche Bank does not render legal or tax advice, and the information contained in this communication should not be regarded as such.